Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Cystic Fibrosis
Interventions
DRUG

ELX/TEZ/IVA

Fixed-dose combination granules or tablets for oral administration.

DRUG

IVA

Granules or tablets for oral administration.

Trial Locations (22)

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

27599

NC TraCS Institute - CTRC University of North Carolina at Chapel Hill, Chapel Hill

46202

Riley Hospital for Children at Indiana University Health, Indianapolis

55404

Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota, Minneapolis

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

Washington University School of Medicine / St. Louis Children's Hospital, St Louis

64108

The Children's Mercy Hospital, Kansas City

80045

Children's Hospital of Colorado, Aurora

85724

Banner University of Arizona Medical Center, Tucson

94304

Stanford University, Palo Alto

97239

Oregon Health & Science University, Portland

98105

Seattle Children's Hospital, Seattle

02115

Boston Children's Hospital, Boston

Unknown

Telethon Kids Institute, Nedlands

The Royal Children's Hospital, Parkville

Queensland Children's Hospital, South Brisbane

The Hospital for Sick Children, Toronto

British Columbia Children's Hospital, Vancouver

Charite Paediatric Pulmonology Department, Berlin

Universitatsklinikum Essen (AoR), Kinderklinik III, Abt. fur Pneumologie, Essen

Alder Hey Children's NHS Foundation Trust, Liverpool

Royal Brompton Hospital, London

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY